Therapeutic Targeting of Myc
Author(s) -
Edward V. Prochownik,
Peter K. Vogt
Publication year - 2010
Publication title -
genes and cancer
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.883
H-Index - 71
eISSN - 1947-6027
pISSN - 1947-6019
DOI - 10.1177/1947601910377494
Subject(s) - medicine , intensive care medicine , bioinformatics , biology
Protein-protein interactions between members of the Myc transcription factor network are potential targets of small molecule inhibitors and stabilizers. Diverse screening strategies, including fluorescence resonance energy transfer, fluorescence polarization, two hybrid and protein complementation assays have identified several lead compounds that inhibit Myc-Max dimerization and one compound that stabilizes the Max homodimer. Representative compounds interfere with Myc-induced transcriptional activation, Myc-mediated oncogenic transformation, Myc-driven cellular replication and DNA binding of Myc. For the best characterized compounds, specific binding sites have been determined, and molecular mechanisms of action have been documented. This knowledge of small molecule - protein interaction is currently applied to highly targeted approaches that seek to identify novel compounds with improved potency.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom